TK-NOG

TK-NOG Mouse Model

NOD Background

  • Model #
  • Genotype
  • Nomenclature
  • 12907-F
    sp/sp;ko/ko;tg/wt
    NOD.Cg-Prkdcscid Il2rgtm1Sug Tg(Alb-TK)7-2/ShiJic
  • 12907-M
    sp/sp;ko/y;tg/wt
    NOD.Cg-Prkdcscid Il2rgtm1Sug Tg(Alb-TK)7-2/ShiJic
  • Super immunodeficient NOG mouse with transgenic expression of thymidine kinase under control of liver-restricted albumin promoter
  • Useful for humanizing liver via engraftment with human hepatocytes and/or humanizing immune system via engraftment of human immune cells/tissues or hematopoietic stem cells
  • Inducible ablation of murine hepatocytes by ganciclovir treatment enables stable, long-term engraftment of human hepatocytes.
  • The premiere model for human liver toxicity, metabolism, and infectious disease.
  • Other uses include safety and immunogenicity assessment
  • Liver/Immune humanized TK-NOG mice are under development. Please contact us to learn more about availability of these tissue humanized TK-NOG Mice.
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Origin:

The NOG mouse was developed by Mamoru Ito of the Central Institute for Experimental Animals (CIEA) in Japan. The Prkdc scid mutation was identified by Mel Bosma of the Fox Chase Cancer Center in a C.B-17 congenic mouse population. This mutation was backcrossed onto the NOD/ShiJic strain at CIEA for at least eight generations. The Il2rg targeted mutation was developed by Dr. Kazuo Sugamura of Tohoku University by targeting the gene in ES cells derived from a 129 strain. Targeted ES cells were injected into C57BL/6 blastocysts. Resultant chimeras were backcrossed onto the C57BL/6JJic background for at least eight generations. The NOG mouse was developed by backcrossing the C57BL/6JJic-Il2rg line to the NOD/ShiJic-Prkdc scid line for a total of eight generations. The HSVtk transgene was generated by CIEA via microinjection into NOD/Shi inbred mice. The transgenic construct contains the mouse albumin enhancer/promoter (mAlb En/Pro), the chimeric intron, HSVtk cDNA, and the 3'-UTR of the human growth hormone gene with a polyadenylation signal (hGH pA). There was a single site of transgene integration, and HSVtk mRNA was selectively expressed in the liver. The TK-NOD/Shi mice were backcrossed onto the NOG mouse at CIEA and imported into Taconic in 2014.


Color:

Albino

Species:

Mouse

Initial Publication:

Hasegawa M, Kawai K, Mitsui T, Taniguchi K, Monnai M, Wakui M, Ito M, Suematsu M, Peltz G, Nakamura M, Suemizu H. The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. (2011) Biochem Biophys Res Commun. 18;405(3):405-10.

Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, Heike T, Nakahata T. (2002) NOD/SCID/γnull/c mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100(9):3175-3182.



Nonprofit users (excluding users at nonprofit foundations which are affiliated with a for-profit entity): For internal research purposes, the CIEA NOG mouse® Conditions of Use for nonprofit users apply. If you wish to perform sponsored research or fee-for-service contract research using the CIEA NOG mouse®, please inquire for access conditions

For-profit users and users at foundations which are affiliated with for-profit entities: The CIEA NOG mouse® Conditions of Use for for-profit users apply.

Does your research require the use of neonates? Please contact us for more information on neonate access options.

The CIEA NOG mouse® is produced and distributed under license rights to the following patents and trademarks:
  • Japanese Patent No. 3,753,321
  • US Patent No. 7,145,055; 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,789,215; 6,204,061; 6,653,113; 6,689,610
    EP Patent No. 1,338,198
  • Japanese Trademark Reg. No. 4,823,423
  • US Trademark Reg. No. 3,118,040
  • EU Trademark Reg. No. 3,736,758